Gilead's rejected patent application highlights Section 3(d) uncertainties
Nearly two years after the Novartis decision, questions about India's Section 3(d) remain
The patent office's written decision points to some unanswered questions surrounding Section 3(d) of the Patents Act. The provision states that where an applicant seeks to patent a new form of a known substance, the application must show that the...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.